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INTRODUCTION
Neuroleptic malignant syndrome (NMS) is an uncommon
but potentially lethal adverse reaction to neuroleptic drugs
that is characterized by autonomic instability, extrapyrami-
dal symptoms (EPS), hyperthermia, and altered mental sta-
tus (1). Dehydration, exhaustion, and psychomotor agita-
tion have been reported to increase the risk of NMS (2).
In this report, we describe a patient with chronic schizophre-
nia who developed probable NMS following the addition of
antituberculotic drugs to his antipsychotic regimen.
CASE REPORT
A 42-yr-old man who had been in and out of psychiatric
hospitals repeatedly since having been diagnosed with schizo-
phrenia in his late teens, according to DSM-IV criteria, pre-
sented to the emergency room (E.R.) with an immediate his-
tory of vomiting, rigidity, and tremor. The patient had been
treated with chlorpromazine 600 mg and benztropine 1 mg
daily on an outpatient basis before coming to the E.R. Sev-
eral months before visiting the E.R., the patient had a cough,
felt chilled, and experienced a cold sweat. He visited the inter-
nal medicine department of another hospital for these symp-
toms and he was diagnosed with active pulmonary tubercu-
losis. Six days before visiting the E.R., he started taking anti-
tuberculotic drugs (rifampin 600 mg, isoniazid 400 mg, and
pyrazinamide 1,500 mg, daily). Four days before visiting
the E.R., his sleep became disturbed, and his speech became
limited. Rigidity in all four extremities and tremor in both
arms were observed at this time. He also vomited twice before
being taken to the E.R. of the university hospital.
His arterial blood pressure was 126/76 mmHg, heart rate
was 120 beats/min, and body temperature was 37℃. The
patient was delirious, and his verbal output was sparse. He
showed severe ‘‘lead pipe’’ rigidity and frequent hand tremor.
Abnormal laboratory findings included elevated serum cre-
atine kinase (CK 2296.9 IU/L and CK-MB 11.2 ng/mL),
uric acid (16.4 mg/dL), aspartate aminotransferase (AST 57
IU/L), glucose (158 mg/dL), myoglobin (557.4 ng/mL), and
decreased serum blood urea nitrogen (BUN 6 mg/dL). The
serum electrolyte panel (sodium 140 mM/L, potassium 3.7
mM/L, chloride 107 mM/L, carbon dioxide 25 mM/L) and
calcium (8.9 mg/dL) were within normal ranges. Leukocy-
tosis was not present, and the pre- and postcontrast brain
CT scan did not reveal any abnormal findings. 
On the first day in the E.R., chlorpromazine, benztropine,
and antituberculotic drugs were discontinued simultane-
ously, and vigorous intravenous hydration and Foley catheter
insertion were carried out to prevent acute renal failure. On
the third day in the E.R., the patient was alert and oriented,
and subjective improvement was reported. The serum myo-
globin level was also normal (46.0 ng/mL). On the fourth
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Probable Case of Neuroleptic Malignant Syndrome Following 
Administration of Antituberculotic Drugs in a Chlorpromazine-Treated
Patient
Neuroleptic malignant syndrome (NMS), a potentially fatal adverse reaction to neu-
roleptics, is known to occur more often in the initial stage of antipsychotic treatment.
We describe a patient with chronic schizophrenia who, in a few days after the addi-
tion of antituberculotic drugs to his antipsychotic regimen, developed probable NMS
without pyrexia. We reasoned that rifampin, a strong hepatic enzyme inducer, dec-
reased the plasma chlorpromazine concentration of the patient, with the result of
cholinergic hyperactivity and finally, the symptoms of NMS. Therefore, physicians
should be aware of drug interactions and the likelihood of NMS, and consider antipsy-
chotic dose adjustment when prescribing drugs that may influence pharmacokinet-
ic properties of antipsychotics in a patient with schizophrenia receiving long-term
antipsychotic treatment.
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day in the E.R., the rigidity in all four extremities improved,
but he was still unable to sit up in bed without assistance.
The Foley catheter was removed, but hydration was main-
tained. On the fifth day in the E.R., the serum CK level dec-
reased to 403 IU/L. The patient was alert, ambulatory with
help, and was discharged with a psychiatric appointment 1
week later, but without an antipsychotic prescription. One
week after discharge, he was rechallenged with an antipsy-
chotic, risperidone 1 mg daily, because of aggravated psy-
chotic symptoms. About 3 months after discharge, he has
not shown any specific neuropsychiatric sequelae of NMS
and has taken antipsychotics and antituberculotic drugs reg-
ularly without any serious adverse events.
DISCUSSION
The diagnosis of NMS has been based on clinical manifes-
tations because the definite cause of NMS is still unknown.
Levenson (1) suggested that the diagnosis of NMS is highly
likely when three major symptoms (fever, muscle rigidity or
EPS, and elevated CK level) or two major and two minor
symptoms (tachycardia, abnormal blood pressure, tachyp-
nea, altered consciousness, diaphoresis, and leukocytosis) are
present. These criteria differ slightly from the DSM-IV TR
criteria, in which severe muscle rigidity and elevated tem-
perature are essential for the diagnosis of NMS. Fever is gen-
erally considered to be an essential feature of NMS, but a
few reported cases have had many features of NMS without
fever, or without initial fiver (3-5). Woodbury and Wood-
bury (6) suggested that it may be a stage in the progression
toward NMS and proposed that there is a spectrum of NMS.
Although the patient did not exhibit a fever, he showed
severe muscle rigidity, an elevated CK level, tachycardia,
and an altered mental status. In addition, his symptoms
markedly improved after neuroleptic and antituberculotic
drugs were discontinued and vigorous intravenous hydra-
tion was carried out. After considering all the above factors,
we concluded that this was an atypical NMS, namely, NMS
without pyrexia.
The other interesting feature of this case is that the NMS
developed shortly after the coadministration of antitubercu-
lotic drugs in a patient taking chlorpromazine alone for schi-
zophrenia. Rifampin is a strong inducer of hepatic cytochrome
P450 (CYP) 3A enzymes and increases the hepatic metabo-
lism of many drugs (7). Most dopamine receptor antagonists
are metabolized by the cytochrome P450 2D6 and P450 3A
enzymes. Accordingly, the plasma concentrations and thera-
peutic effects of antipsychotics can be reduced by the admin-
istration of rifampin. Kim et al. (8) reported that a decrease
in the plasma haloperidol concentration due to rifampin
administration developed rapidly and that the extent was
large in several patients. Gorski et al. (7) demonstrated that
there is a large interindividual variability in the extent of CYP
3A induction by rifampin. Thus, we reasoned that this pati-
ent’s chlorpromazine blood level was decreased by the admin-
istration of rifampin.
A few cases of NMS after the discontinuation of antido-
paminergic or anticholinergic treatment have been reported
(9, 10). Chronic treatment with haloperidol and piperazine
phenothiazines actually inhibits the release of acetylcholine
due to the induction of supersensitivity to dopamine (11).
Moreover, long-term treatment with neuroleptics induces
an up-regulation of muscarinic receptors (mAchR) (12). NMS
following antipsychotic withdrawal, especially in the case of
long-term treatment with antipsychotics, is probably relat-
ed to cholinergic overdrive in addition to a dopaminergic
‘imbalance’ or dysregulation. Amore and Zazzeri (12) sug-
gested that on neuroleptic withdrawal, a cholinergic hyper-
activity can occur, resulting in a state of relatively reduced
dopaminergic transmission, and that cholinergic hyperactivi-
ty seems to be a critical point in precipitating NMS. Chlor-
promazine, which was taken in the present case, has marked
anticholinergic properties. Consequently, we hypothesized
that the plasma chlorpromazine concentration of the patient
was decreased after the administration of rifampin, with the
result of cholinergic hyperactivity and finally, the symptoms
of NMS.
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